Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed/Refractory Indolent T/NK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial

NCT06716658 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06716658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed/Refractory Indolent T/NK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Overall status
Recruiting
Start date
December 25, 2024
Completion date
November 15, 2028
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma, cutaneous t cell lymphoma (ctcl), indolent t-cell lymphoproliferative disorder of the gastrointestinal tract, large granular lymphocyte leukemia, large granular lymphocytic leukemia, lymphoma, t-cell, mycosis fungoides, nk-lgl leukemia, primary cutaneous acral cd8-positive t-cell lymphoma, t-lgl leukemia